Kineta, Inc. (KANT)
OTCMKTS
· Delayed Price · Currency is USD
0.390
-0.028 (-6.70%)
Mar 25, 2025, 4:00 PM EST
Kineta Employees
As of December 31, 2024, Kineta had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees decreased by 8 or -61.54% compared to the previous year.
Employees
5
Change (1Y)
-8
Growth (1Y)
-61.54%
Revenue / Employee
n/a
Profits / Employee
-$3,426,400
Market Cap
4.78M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | -8 | -61.54% |
| Dec 31, 2023 | 13 | 1 | 8.33% |
| Dec 31, 2022 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 2,931 |
| Elite Pharmaceuticals | 64 |
| Glass House Brands | 413 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 9 |
| Silence Therapeutics | 116 |
| American Oncology Network | 1,525 |
Kineta News
- 3 months ago - SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT - PRNewsWire
- 3 months ago - KANT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kineta, Inc. Is Fair to Shareholders - Business Wire
- 4 months ago - Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024) - GlobeNewsWire
- 6 months ago - Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - GlobeNewsWire
- 6 months ago - Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1 - GlobeNewsWire
- 6 months ago - Kineta, Inc Transitioning from Nasdaq to OTC Markets - GlobeNewsWire